Literature DB >> 21518779

Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells.

I-Wen Teng1, Pei-Chi Hou, Kuan-Der Lee, Pei-Yi Chu, Kun-Tu Yeh, Victor X Jin, Min-Jen Tseng, Shaw-Jenq Tsai, Yu-Sun Chang, Chi-Sheng Wu, H Sunny Sun, Kuen-Daw Tsai, Long-Bin Jeng, Kenneth P Nephew, Tim H-M Huang, Shu-Huei Hsiao, Yu-Wei Leu.   

Abstract

Although DNA hypermethylation within promoter CpG islands is highly correlated with tumorigenesis, it has not been established whether DNA hypermethylation within a specific tumor suppressor gene (TSG) is sufficient to fully transform a somatic stem cell. In this study, we addressed this question using a novel targeted DNA methylation technique to methylate the promoters of HIC1 and RassF1A, two well-established TSGs, along with a two-component reporter system to visualize successful targeting of human bone marrow-derived mesenchymal stem cells (MSC) as a model cell system. MSCs harboring targeted promoter methylations of HIC1/RassF1A displayed several features of cancer stem/initiating cells including loss of anchorage dependence, increased colony formation capability, drug resistance, and pluripotency. Notably, inoculation of immunodeficient mice with low numbers of targeted MSC resulted in tumor formation, and subsequent serial xenotransplantation and immunohistochemistry confirmed the presence of stem cell markers and MSC lineage in tumor xenografts. Consistent with the expected mechanism of TSG hypermethylation, treatment of the targeted MSC with a DNA methyltransferase inhibitor reversed their tumorigenic phenotype. To our knowledge, this is the first direct demonstration that aberrant TSG hypermethylation is sufficient to transform a somatic stem cell into a fully malignant cell with cancer stem/initiating properties. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21518779     DOI: 10.1158/0008-5472.CAN-10-3418

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway.

Authors:  F Neri; D Dettori; D Incarnato; A Krepelova; S Rapelli; M Maldotti; C Parlato; P Paliogiannis; S Oliviero
Journal:  Oncogene       Date:  2014-11-03       Impact factor: 9.867

Review 2.  A decade of exploring the cancer epigenome - biological and translational implications.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 3.  Stages based molecular mechanisms for generating cholangiocytes from liver stem/progenitor cells.

Authors:  Wei-Hui Liu; Li-Na Ren; Tao Chen; Li-Ye Liu; Li-Jun Tang
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

4.  Measurement of DNA Length Changes Upon CpG Hypermethylation by Microfluidic Molecular Stretching.

Authors:  Daisuke Onoshima; Naoko Kawakita; Daiki Takeshita; Hirohiko Niioka; Hiroshi Yukawa; Jun Miyake; Yoshinobu Baba
Journal:  Cell Med       Date:  2016-09-14

5.  Curcumin causes promoter hypomethylation and increased expression of FANCF gene in SiHa cell line.

Authors:  Gaurav Parashar; Nidarshana Chaturvedi Parashar; Neena Capalash
Journal:  Mol Cell Biochem       Date:  2012-06       Impact factor: 3.396

Review 6.  A Tox21 Approach to Altered Epigenetic Landscapes: Assessing Epigenetic Toxicity Pathways Leading to Altered Gene Expression and Oncogenic Transformation In Vitro.

Authors:  Craig L Parfett; Daniel Desaulniers
Journal:  Int J Mol Sci       Date:  2017-06-01       Impact factor: 5.923

7.  Expression of the TIMP2 gene is not regulated by promoter hypermethylation in the Caski cell line.

Authors:  Gaurav Parashar; Neena Capalash
Journal:  Oncol Lett       Date:  2012-02-13       Impact factor: 2.967

8.  A Disintegrin and A Metalloproteinase-9 (ADAM9): A Novel Proteinase Culprit with Multifarious Contributions to COPD.

Authors:  Xiaoyun Wang; Francesca Polverino; Joselyn Rojas-Quintero; Duo Zhang; José Sánchez; Ilyas Yambayev; Eva Lindqvist; Robert Virtala; Ratko Djukanovic; Donna E Davies; Susan Wilson; Rory O'Donnell; Danen Cunoosamy; Petra Hazon; Andrew Higham; Dave Singh; Henric Olsson; Caroline A Owen
Journal:  Am J Respir Crit Care Med       Date:  2018-06-04       Impact factor: 21.405

Review 9.  Cellular reprogramming and hepatocellular carcinoma development.

Authors:  Yun-Wen Zheng; Yun-Zhong Nie; Hideki Taniguchi
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

Review 10.  The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment.

Authors:  Yanghong Ni; Xiaoting Zhou; Jia Yang; Houhui Shi; Hongyi Li; Xia Zhao; Xuelei Ma
Journal:  Front Cell Dev Biol       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.